Indolyl aryl sulphones as HIV-1 non-nucleoside reverse transcriptase inhibitors: Synthesis, biological evaluation and binding mode studies of new derivatives at indole-2-carboxamide

Antiviral Chemistry and Chemotherapy

Volumn 17, Issue 2, 2006, Pages 59-77

  De Martino, Gabriella ^a   La Regina, Giuseppe ^a   Ragno, Rino ^a   Coluccia, Antonio ^a   Bergamini, Alberto ^b   Ciaprini, Chiara ^b   Sinistro, Anna ^b   Maga, Giovanni ^c   Crespan, Emmanuele ^c   Artico, Marino ^a   Silvestri, Romano ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c CNR   (Italy)

Author keywords

AIDS; HIV; IAS; NNRTI; Reverse transciptase

Indexed keywords

ANTIVIRUS AGENT; DELAVIRDINE; EFAVIRENZ; L 737 126; N (2 HYDROXYETHYL) 3 (PHENYLSULPHONYL) 5 CHLORO 1H INDOLE 2 CARBOXAMIDE; N (2 HYDROXYETHYL) 3 [(2 METHYLPHENYL)SULPHONYL] 5 CHLORO 1H INDOLE 2 CARBOXAMIDE; N (2 HYDROXYETHYL) 3 [(2 METHYLPHENYL)THIO] 5 CHLORO 1H INDOLE 2 CARBOXAMIDE; N (2 HYDROXYETHYL) 3 [(2,4 DIMETHYLPHENYL)THIO] 5 CHLORO 1H INDOLE 2 CARBOXAMIDE; N (2 HYDROXYETHYL) 3 [(3 METHYLPHENYL)SULPHONYL] 5 CHLORO 1H INDOLE 2 CARBOXAMIDE; N (2 HYDROXYETHYL) 3 [(3 METHYLPHENYL)THIO] 5 CHLORO 1H INDOLE 2 CARBOXAMIDE; N (2 HYDROXYETHYL) 3 [(3,5 DIMETHYLPHENYL)THIO] 5 CHLORO 1H INDOLE 2 CARBOXAMIDE; N (2 HYDROXYETHYL) 3 [(4 METHYLPHENYL)SULPHONYL] 5 CHLORO 1H INDOLE 2 CARBOXAMIDE; N (2 HYDROXYETHYL) 3 [(4 METHYLPHENYL)THIO] 5 CHLORO 1H INDOLE 2 CARBOXAMIDE; N (2 HYDROXYETHYL)CARBOXAMIDE DERIVATIVE; N' (2 HYDROXYETHYL) 3 (PHENYLSULPHONYL) 5 CHLORO 1H INDOLE 2 CARBOHYDRAZIDE; N' (2 HYDROXYETHYL) 3 (PHENYLTHIO) 5 CHLORO 1H INDOLE 2 CARBOHYDRAZIDE; N' (2 HYDROXYETHYL) 3 [(2 METHYLPHENYL)SULPHONYL] 5 CHLORO 1H INDOLE 2 CARBOHYDRAZIDE; N' (2 HYDROXYETHYL) 3 [(2 METHYLPHENYL)THIO] 5 CHLORO 1H INDOLE 2 CARBOHYDRAZIDE; N' (2 HYDROXYETHYL) 3 [(2,4 DIMETHYLPHENYL)SULPHONYL] 5 CHLORO 1H INDOLE 2 CARBOHYDRAZIDE; N' (2 HYDROXYETHYL) 3 [(3,5 DIMETHYLPHENYL)THIO] 5 CHLORO 1H INDOLE 2 CARBOHYDRAZIDE; N' (2 HYDROXYETHYL) 3 [(4 METHYLPHENYL)SULPHONYL] 5 CHLORO 1H INDOLE 2 CARBOHYDRAZIDE; N' (2 HYDROXYETHYL) 3 [(4 METHYLPHENYL)THIO] 5 CHLORO 1H INDOLE 2 CARBOHYDRAZIDE; N' (2 HYDROXYETHYL)CARBOHYDRAZIDE DERIVATIVE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SULFONE; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG DESIGN; DRUG POTENCY; DRUG SENSITIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROPHILICITY; LIPOPHILICITY; MOLECULAR MODEL; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT; VIRUS MUTANT; WILD TYPE;

EID: 33646455456     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020601700202     Document Type: Article

References (40)

1. Andreoni M, Sarmati L, Parisi SG, Ercoli L & Rocchi G (1992) Efficient and reproducible new semimicromethod for the detection and tritation of HIV in human plasma. Journal of Medical Virology 38:207-213.
2. Artico M, Silvestri R, Massa S, Loi AG, Corrias S, Piras G & La Colla P (1996) 2-Sulfonyl-4-chloroanilino moiety: a potent pharmacophore for the anti-human immunodeficiency virus type 1 activity of pyrrolyl aryl sulfones. Journal of Medicinal Chemistry 39:522-530.
3. Artico M, Silvestri R, Pagnozzi E, Bruno B, Novellino E, Greco G, Massa S, Ettorre A, Loi AG, Scintu F & La Colla P (2000) Structure-based design, synthesis and biological evaluation of novel pyrrolyl aryl sulfones (PASs), HIV-1 non-nucleoside reverse transcriptase inhibitors active at nanomolar concentrations. Journal of Medicinal Chemistry 43:1886-1891.
4. Artico M (1996) Non-nucleoside anti-HIV-1 reverse transcriptase inhibitors (NNRTIs): a chemical survey from lead compounds to selected drugs for clinical trials. Farmaco 51:305-331.
5. Baldanti F, Paolucci S, Maga G, Labo N, Hübscher U, Skoblov AY, Victorov L, Spadari S, Minoli L & Gerna G (2003) Nevirapine-selected mutations reverse transcriptase confer cross-stavudine. AIDS 17:6-8.
6. Bergamini A, Capozzi M, Ghibelli L, Dini L, Salanitro A, Milanese G, Wagner T, Beninati S, Pesce CD, Amici C & Rocchi G (1994) Cystamine potently suppresses in vitro HIV replication in acutely and chronically infected human cells. Journal of Clinical Investigation 93:2251-2257.
7. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN & Bourne PE (2000) The Protein Data Bank. Nucleic Acids Research 28:235-242.
8. Blanca G, Baldanti F, Paolucci S, Skoblov AY, Victorova L, Hübscher U, Gerna G, Spadari S & Maga G (2003) Nevirapine resistance mutation at codon 181 of the HIV-1 reverse transcriptase confers stavudine resistance by increasing nucleotide substrate discrimination and phosphorolytic activity. Journal of Biological Chemistry 18:15469-15472.
9. Buckheit RW (2001) Non-nucleoside reverse transcriptase inhibitors: perspectives on novel therapeutic compounds and strategies for the treatment of HIV infection. Expert Opinion on Investigational Drugs 10:1423-42.
10. Chou TC (1976) Derivation and properties of Micaelis-Menten type and Hill type equation for reference ligands. Journal of Theoretical Biology 59:253-276.
11. Corbett JW & Rodgers JD (2002) Discovery of second generation quinazolinone non-nucleoside reverse transcriptase inhibitors of HIV-1. Progress in Medicinal Chemistry 40:63-105.
12. De Clercq E (2002) New anti-HIV agents and targets. Medicinal Research Reviews 6:531-565.
13. De Clercq E (2004) Non-nucleoside anti-HIV-1 reverse transcriptase inhibitors (NNRTIs): past, present and future. Chemistry & Biodiversity 1:44-64.
14. De Clercq E (2005) New approaches toward anti-HIV chemotherapy. Journal of Medicinal Chemistry 48:1297-1313.
15. Goodsell DS, Morris GM & Olson AJ (1996) Automated docking of flexible ligands: applications of AutoDock. Journal of Molecular Recognition 9:1-5.
16. Guex N & Peitsch MC (1997) SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modelling. Electrophoresis 18:2714-2723
17. Huang CC, Couch GS, Pettersen EF & Ferrin TE (1996) In Chimera: an extensible molecular modelling application constructed using standard components, Pacific Symposium on Biocomputing, 724.
18. Karber G (1931) Beitrag zur kollectiven Behandlung Pharmakologisher Reihenversuche [German] [Contribution to the collective treatment of pharmacological research]. Archive der Experimentell Pharmakologie 162:480-483.
19. Maga G, Amacker M, Ruel N, Hubsher U & Spadari S (1997) Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions. Journal of Molecular Biology 274:738-747.
20. McLachlan AD (1982) Rapid comparison of protein structures. Acta Crystallographica, Section A: crystal physics, diffraction, theoretical and general crystallography A38:871-873
21. Mohamadi F, Richards NGJ, Guida WC, Liskamp R, Lipton M, Caufield C, Chang G, Hendrickson T & Still WC (1990) MacroModel-An Integrated Software System for Modelling Organic and Bioorganic Molecules Using Molecular Mechanics. Journal of Computational Chemistry 11:440-467.
22. Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D, Hederwijn P, Desmyster J & De Clercq E (1988). A rapid and automated tetrazolium-based colorimetric assay for the detection of anti HIV compounds. Journal of Virological Methods 20:309-321.
23. Pearlman DA, Case DA, Caldwell JW, Ross S, Cheatham TE III, DeBolt S, Ferguson D, Seibel G & Kollman P (1995) 'AMBER', a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to stimulate the structural and energetic properties of molecules. Computer Physics Communication 91:1-42.
24. Perno CF, Yarchoan R, Cooney DA, Hartman NR, Gartner S, Popovic M, Hao Z, Gerrard TL, Wilson YA & Johns DG (1998) Inhibition of human immunodeficiency virus (HIV-17, HTLV-III-Ba-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2′,3′-didesoxynucleosides. Journal of Experimental Medicine 168:1111-1125.
25. Placido R, Mancino G, Amendola A, Mariani F, Venditti S, Piacentini M, Sanduzzi A, Bocchino ML, Zembala M & Colizzi, V (1997) Apoptosis of human monocytes/macrophages in Mycobacterium tubercolosis infection. Journal of Pathology 181:31-38.
26. Ragno R, Artico R, De Martino G, La Regina G, Coluccia A, Di Pasquali A & Silvestri R (2005G) Docking and 3-D QSAR Studies on Indolyl Aryl Sulfones (IASs). Binding Mode Exploration at the HIV-1 Reverse Transcriptase Non-Nucleoside Binding Site and Design of Highly Active N-(2-Hydroxyethyl) carboxamide and N-(2-Hydroxyethyl) carboxy hydrazide Derivatives. Journal of Medicinal Chemistry 48:213-223
27. Ragno R, Frasca S, Manetti F, Brizzi A & Massa S (2005b) HIV-1 Reverse trascriptase inhibition: inclusion of ligand-induced fit by cross-docking studies. Journal of Medicinal Chemistry 48:200-212.
28. Ren J, Esnouf R, Garman E, Somers D, Ross C, Kirby I, Keeling J, Darby G, Jones Y & Stuart D (1995) High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nature Structural Biology 2:293-302.
29. Ren J, Milton J, Weaver KL, Short SA, Stuart DI & Stammers DK (2000) Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. Structure 8:1089-1094
30. Ren J, Nichols C, Bird L, Chamberlain P, Weaver K, Short S, Stuart DI & Stammers DK (2001) Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. Journal of Molecular Biology 312:795-805.
31. Ren J, Nichols CE, Chamberlain PP, Weaver KL, Short SA & Stammers DK (2004) Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors. Journal of Molecular Biology 336:569-578.
32. Silvestri R, Artico M, De Martino G, La Regina G, Loddo R, La Colla M & La Colla P (2004) Simple, short peptide derivatives of L-737,126 active in vitro against HIV-1 WT and variants carrying NNRTI resistance mutations. Journal of Medicinal Chemistry 47:3892-3896.
33. Silvestri R, De Martino G, Artico M, Massa S, Marceddu T, Loi AG, Musiu C & La Colla C (2003) Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: synthesis and SAR studies. Journal of Medicinal Chemistry 46:2482-2493.
34. Sodroski JG, Rosen CA & Haseltine WA (1984) Trans-acting transcritional activation of the long terminal repeat of human lymphotropic viruses in infected cells. Science 225:381-385.
35. Tachedjian G & Goff SP (2003) The effect of NNRTIs on HIV reverse transcriptase dimerization. Current Opinion in Investigational Drugs 4:966-973.
36. Tetko IV & Tanchuk VY (2002) Application of Associative Neural Networks for Prediction of Lipophilicity in ALOGPS 2.1 Program. Journal of Chemical Information and Computer Sciences 42:1136-1145
37. Vandamme A-M, Van Vaerenbergh K & De Clercq E (1998) Anti-human immunodeficiency virus drug combination strategies. Antiviral Chemistry & Chemotherapy. 9:187-203.
38. WHO/UNAIDS. AIDS Epidemic Update: December 2003.
39. Williams IG (2003) Enfuvirtide (Fuzeon): the first fusion inhibitor. International Journal of Clinical Practice 57:890-897.
40. Williams TM, Ciccarone TM, Saari WS, Wai JS, Greenlee WJ, Balani SK, Goldman ME, Hoffman JM Jr, Lumma WC Jr, Huff J, Rooney C, Sanderson PE & Theoharides AD (1994) Indole derivatives as inhibitors of HIV reverse transcriptase. Patent PCT Int. Appl, WO 9419321.